Challenges of advanced hepatocellular carcinoma

Table 2 Results of studies with molecular targeted therapies as first line in advanced hepatocellular carcinoma

Treatment	Trial	OS	TTP	Ref.
Sorafenib	Phase III vs placebo	10.7 mo vs 7.9 mo, P < 0.001;	5.5 mo vs 2.8 mo, P < 0.001	[10]
	(SHARP)	HR = 0.69; 95%CI: 0.55-0.87
Sorafenib	Phase III vs placebo	6.5 mo vs 4.2 mo, P = 0.014;	2.8 mo vs 1.4 mo, P = 0.0005;	[11]
	(Asia-Pacific)	HR = 0.68; 95%CI: 0.50-0.93	HR = 0.57; 95%CI: 0.42-0.79
Sunitinib	Phase III vs sorafenib	7.9 mo vs 10.2 mo, P = 0.0019; HR = 1.30; 95%CI: 1.13-1.50	4.1 mo vs 3.8 mo, one-sided P = 0.8312;	[31]
	(SUN)		two-sided P = 0.3082; HR = 1.13
Brivanib	Phase III vs sorafenib	9.5 mo vs 9.9 mo, P = 0.3116;	4.2 mo vs 4.1 mo, P = 0.853;	[32]
	(BRISK-FL)	HR = 1.07; 95%CI: 0.94-1.23	HR = 1.01; 95%CI: 0.88-1.16
Linifanib	Phase III vs sorafenib	9.1 mo vs 9.8 mo, P = NS;	5.4 mo vs 4.0 mo, P = 0.001;	[33]
		HR = 1.05; 95%CI: 0.90-1.22	HR = 0.759; 95%CI: 0.64-0.895
Erlotinib	Phase III erlotinib plus sorafenib and eorafenib plus placebo (SEARCH)	9.5 mo vs 8.5 mo, P = 0.408;	3.2 mo vs 4.0 mo, P = NS;	[36]
		HR = 0.929	HR = 1.135; P = 0.18

OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression; CI: Confidence interval; HR: Hazard ratio; NS: Not significant.